• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novo Nordisk

292.40 DKK-0.78 %17.8, 17.09
1,067 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.78 %
-12.92 %
-2.27 %
-4.96 %
-10.10 %
-10.28 %
-53.87 %
-9.88 %
+23,385.94 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.31T DKK
Turnover
1B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
12.68
Dividend yield-%
4 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
Novo is certainly in for quite a struggle. The report was absolutely dire, even though the guidance for this year was raised. Investors, however, are looking ahead to the 2031-2032 period, when the patents for semaglutide expire. At the moment, it looks really bad. Ziltivekimab was...
8/5/2026, 7:29 PM
by MolskisPabrai
52
Novo has launched its new Awiqli insulin in the United States for type 2 diabetes. Its greatest advantage is that the insulin only needs to be injected once a week instead of the current daily injection. According to studies, it worked just as well in blood sugar management as daily...
8/11/2026, 1:51 PM
by Sijoittaja-alokas
34
This post is so negative that it made me take a look at the author’s previous posts. The writing seems to be in line with posts from several years ago, which explains why the author interprets even positive drivers as negative forecasts in the text. Criticism is always a good thing...
8/6/2026, 6:38 AM
by Kari Kokkonen
19
Picked up a recent CNBC interview from Nordnet where CEO Mike Doustdar breaks down the current situation and the optimistic outlook in plain language.
8/7/2026, 2:46 PM
by Keepitcoming
13
Novo has sued Eli Lilly over what it considers misleading advertising for a weight-loss drug. In the ad, Lilly compares Zepbound to an older and milder dose of Wegovy, even though Novo already has a newer and more effective version available. Lilly emphasizes that its comparison ...
8/13/2026, 4:25 AM
by Sijoittaja-alokas
6
GLP-1 is balancing between strong growth and price erosion. Falling prices are rapidly increasing demand and sales, but at the same time, the product’s gross margin is naturally decreasing. Ultimately, this is a long game. Through a strong increase in production volumes, unit costs...
8/5/2026, 5:32 AM
by Kari Kokkonen
6
It was already known that Lilly is a red flag for the company. The competition is tough, but without competition, there is no development, right? I wouldn’t be too worried; there might be some turbulence in the short term.
8/5/2026, 6:17 AM
5
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.11
2026

Interim report Q3'26

Regulatory press release17.08.2026, 14.21

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 12/08 - INVISIO CEO-interview og fokus på Vestas og Demant
Video12.08.2026, 09.36 by
Rasmus Køjborg, Jacob Frehr

HCA Morgenbørs 12/08 - INVISIO CEO-interview og fokus på Vestas og Demant

Igen udsigt til en afventende åbning i Europa. Stort fokus på Vestas og Demant der begge opjusterer. Gæst i studiet her til morgen er CEO Lars Højgård Hansen fra INVISIO.

Vestas Wind SystemsDemantSampoMatasISSNTG Nordic Transport GroupNovo NordiskINVISIOCadelerColoplast
Regulatory press release10.08.2026, 15.35

Novo Nordisk A/S - share repurchase programme

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release10.08.2026, 14.00

Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI

Novo Nordisk
HCA Morgenbørs 10/08 – GreenMobility CEO interviewes og rolig start på ugen
Video10.08.2026, 09.44 by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 10/08 – GreenMobility CEO interviewes og rolig start på ugen

Udsigt til en rolig start på ugen der igen byder på et væld af regnskaber. Gæst i studiet her til morgen er CEO Kasper Gjedsted fra GreenMobility.

GreenMobilityNovo NordiskRingkjøbing LandbobankRockwoolTormGenmab
HCA Morgenbørs 07/08 - Forsigtigt marked forud for beskæftigelsesrapporten senere i dag
Video07.08.2026, 09.20 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 07/08 - Forsigtigt marked forud for beskæftigelsesrapporten senere i dag

I dagens Morgenbørs ser vi ind i et forsigtigt faldende marked, der afventer den amerikanske beskæftigelsesrapport senere i dag, som kan styrke argumenterne for en rentestigning fra Fed. Herhjemme er der fokus på regnskabsaktuelle Genmab.

GenmabNovo NordiskScandinavian Medical SolutionsWindowMaster InternationalFøroya BankiVestas Wind SystemsA.P. Møller - Mærsk
Regulatory press release06.08.2026, 09.18

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk
HCA Morgenbørs 06/08 - Lettere positiv åbning med investorernes øjne rettet mod Mellemøsten
Video06.08.2026, 09.17 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 06/08 - Lettere positiv åbning med investorernes øjne rettet mod Mellemøsten

I dagens MorgenBørs ser vi ind i et lettere positivt marked, hvor investorernes øjne er rettet mod Mellemøsten og den ventede genåbning af Hormuzstrædet. Herhjemme er der fokus på Genmab forud for regnskabet, der ventes offentliggjort i dag, herudover er der også fokus på Novo Nordisk og NTG.

Novo NordiskRingkjøbing LandbobankCarlsbergRoyal UnibrewGenmabPandora
Press release05.08.2026, 15.42

Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray

Novo Nordisk
HCA Morgenbørs 05/08 - Danske regnskaber i fokus
Video05.08.2026, 10.04 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 05/08 - Danske regnskaber i fokus

I dagens Morgenbørs ser vi ind i en positiv åbning i Europa med håb om en fredsaftale i Iran. Herhjemme er investorernes fokus rettet mod de regnskabsaktuelle selskaber Novo Nordisk, Ringkjøbing Landbobank og Føroya Banki.

Novo NordiskRingkjøbing LandbobankFøroya BankiFLSmidth & Co.ISSPandoraDanske Bank
Analyst Comment04.08.2026, 19.30

HCA Redflag - Novo Nordisk (AI)

The Wegovy pill delivers the strongest GLP-1 launch ever, free cash flow jumps 44%, and management raises its guidance. However, behind the adj. figures, the reported bottom line fell 21%, the pipeline disappointed (ZEUS, monlunabant, CagriSema), and a ~50% price reduction in the US looms from January 1, 2027. We have run the financial statements through our red flag analysis - see the 3 biggest positive and 3 biggest negative share price triggers.

Novo Nordisk
Regulatory press release04.08.2026, 18.36

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

Novo Nordisk
Regulatory press release04.08.2026, 18.33

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Novo Nordisk
Regulatory press release04.08.2026, 15.40

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 04/08 - Positiv åbning på forventninger om en nedtrapning af konflikten i Iran
Video04.08.2026, 09.16 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 04/08 - Positiv åbning på forventninger om en nedtrapning af konflikten i Iran

I dagens Morgenbørs ser vi ind i en positiv åbning, hvor investorerne fortsat forventer en nedtrapning af konflikten i Iran efter Donald Trumps U-vending i søndags. Herhjemme er der blandt andet fokus på Novo Nordisk, Tryg og Sampo.

Novo NordiskTrygSampoFLSmidth & Co.INVISIOGreenMobilityPandoraRockwool
HCA Morgenbørs 03/08 - Prisfald i olie driver positivt marked
Video03.08.2026, 09.28 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 03/08 - Prisfald i olie driver positivt marked

I dagens Morgenbørs ser vi ind i en positiv åbning i Europa, hvor der er store prisfald på olie forud for forhandlingerne mellem USA og Iran. Herhjemme er der blandt andet fokus på Novo Nordisk, ISS og GreenMobility.

Novo NordiskGreenMobilityISSRockwoolVestas Wind Systems
Regulatory press release31.07.2026, 13.20

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Novo Nordisk
Regulatory press release27.07.2026, 12.48

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release21.07.2026, 13.35

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

Novo Nordisk
Regulatory press release20.07.2026, 14.31

Novo Nordisk A/S - share repurchase programme

Novo Nordisk